Hemosiderosis

Hemosiderosis - General Information

Hemosiderosis – Symptoms

Hemosiderosis – Treatment

If the person presents bleeding in the lungs, the treatment focuses on the respiratory therapy, immunosuppression, oxygen, and a blood transfusion if it is necessary. Milk sensitivity can be treated by removing all milk products from the individual’s diet; this may trigger the complete clear up of the bleeding. If the illness is due to another disorder, treating the underlying condition will lessen the bleeding. Studies have not solved the question of whether it is recommended to use immunosuppressive drugs like prednisone that is useful for a long-term treatment of Hemosiderosis. The side effects of the therapy depend on the treatment applied. Side effects of some steroids can include jittery feelings, stomach upset, bloating, muscle weakness, and weight gain. If such a therapy is combined with a long-term treatment with DTPA in beta-thalassemia and desferioxamine other adverse reactions can also emerge. The patients may have many complaints of severe hemoptysis, headaches, weakness, dyspnea, and rhinitis. Chest radiographies will reveal a bilateral patchy infiltrates, and predominantly in some lower parts of both lungs. The severe anemia was treated by some blood transfusions which can be repeated to every 4-5 days. Open lung biopsies displays signs of that diffuse hemorrhage with some hyaline membranes, hemosiderin macrophages, mild interstitial fibrosis, a focal fibroid deposited that contains intermingled histiocytes, and a focal intra-alveolar calcified bodies surrounded by any foreign body giant cells. Analysis of the endogenous lectins has failed to demonstrate the expression of a binding capacity for fucose, maltose, lactose, mannose and sialic acid. Neither the binding capacities for the macrophage migration of inhibitory factor nor its presence, can be detected histochemically. The lights of microscopical research are consistent with any longer/lasting diffuse Pulmonary Hemosiderosis; and the presence of foreign body giant cells and calcified bodies argues for the role of inhaled substances. The patient's clinical state has improved after the cyclophosphamide treatment that restored her ability to work and released him from the need to recurrent blood transfusions.

The results of the study promulgated by researchers as well as the results of the FDA review of chemistry, supportive studies and preclinical pharmacology are described: after the following 48 weeks of treatment in the phase III of study, all patients' liver iron concentrations had decreased in the deferoxamine and deferasirox groups, mostly despite the continued blood transfusions in the both groups. Deferasirox was replaced with the serum creatinine that increases in approximately a third of patients. Some adverse events commonly included are: skin rash and gastrointestinal symptoms. A few data provided to the supportive evidence of deferasirox assurance and efficacy. The conclusions can be the following: the FDA granted to deferasirox accelerated the approval on November 2, 2005, to be used in treating the chronic iron overload due to the transfusional Hemosiderosis in patients for 2 years of age. A physical examination including development and growth is also required in patients with this medical condition. Further studies are done to evaluate the potential iron toxicity. Hepatic enzymes are analyzed. Cardiac electrocardiogram and ejection fraction is required. Glucose tolerance and thyroid function tests are also recommended.